Richard N. Channick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard N. Channick has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Alison S. Witkin
Department of Pulmonary and Critical Care Medicine Massachusetts General Hospital Boston MA USA
2 shared publications Abigail R. Lara
1 shared publicationAlfred A. Bove
1 shared publication- Alison Morris
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA
1 shared publication - Alkis Togias
National Institute of Allergy and Infectious Diseases, Bethesda, MD
1 shared publication - Allan I. Pack
Division of Sleep Medicine/Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA
1 shared publication
Latest Publications
- Open Access
- 28 December 2017
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 12 (1) , 121
Quantifying the learning curve for pulmonary thromboendarterectomy
Pulmonary thromboendarterectomy (PTE) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but is a technically challenging operation for cardiothoracic surgeons. Starting a new program allows an opportunity to define a learning curve for PTE. A retrospective case review was performed of 134 consecutive PTEs performed from 1998 to 2016 at a single institution. Outcomes were compared using either a two-tailed t-test for continuous variables or a chi-squared test for categorical variables according to experience of the program by terciles (T). The 30-day mortality was 3.7%. The mean length of hospital stay, length of ICU stay, and duration on a ventilator were 12.6 days, 4.6 days, and 2.0 days, respectively. The mean decrease in systolic pulmonary artery pressure (sPAP) was 41.3 mmHg. Patients with Jamieson type 2 disease had a greater change in mean sPAP than those with type 3 disease (p = 0.039). The mean cardiopulmonary bypass time was 180 min (T1–198 min, T3–159 min, p = <0.001), and the mean circulatory arrest time was 37 min (T1-44 min, T3-31 min, p < 0.001). Plotting circulatory arrest times as a running sum compared to the mean demonstrated 2 inflection points, the first at 22 cases and the second at 95 cases. PTE is a challenging procedure to learn, and good outcomes are a result of a multi-disciplinary effort to optimize case selection, operative performance, and postoperative care. Approximately 20 cases are needed to become proficient in PTE, and nearly 100 cases are required for more efficient clearing of obstructed pulmonary arteries.
- 28 December 2017
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 12 (1) , 121
Open AccessQuantifying the learning curve for pulmonary thromboendarterectomy
Pulmonary thromboendarterectomy (PTE) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but is a technically challenging operation for cardiothoracic surgeons. Starting a new program allows an opportunity to define a learning curve for PTE. A retrospective case review was performed of 134 consecutive PTEs performed from 1998 to 2016 at a single institution. Outcomes were compared using either a two-tailed t-test for continuous variables or a chi-squared test for categorical variables according to experience of the program by terciles (T). The 30-day mortality was 3.7%. The mean length of hospital stay, length of ICU stay, and duration on a ventilator were 12.6 days, 4.6 days, and 2.0 days, respectively. The mean decrease in systolic pulmonary artery pressure (sPAP) was 41.3 mmHg. Patients with Jamieson type 2 disease had a greater change in mean sPAP than those with type 3 disease (p = 0.039). The mean cardiopulmonary bypass time was 180 min (T1–198 min, T3–159 min, p = <0.001), and the mean circulatory arrest time was 37 min (T1-44 min, T3-31 min, p < 0.001). Plotting circulatory arrest times as a running sum compared to the mean demonstrated 2 inflection points, the first at 22 cases and the second at 95 cases. PTE is a challenging procedure to learn, and good outcomes are a result of a multi-disciplinary effort to optimize case selection, operative performance, and postoperative care. Approximately 20 cases are needed to become proficient in PTE, and nearly 100 cases are required for more efficient clearing of obstructed pulmonary arteries.
- 23 June 2015
- Published by Springer Nature in Current Cardiology Reports
- Vol. 17 (8) , 1-8
Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism
Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when a pulmonary embolism fails to undergo complete thrombolysis leading to vascular occlusion and pulmonary hypertension. Despite the fact that CTEPH is a potential consequence of pulmonary embolism, diagnosis requires a high degree of vigilance as many patients will not have a history of thromboembolic disease. The ventilation perfusion scan is used to evaluate for the possibility of CTEPH although right heart catheterization and pulmonary artery angiogram are needed to confirm the diagnosis. Pulmonary thromboendarterectomy is the first-line treatment for patients who are surgical candidates. Recently, riociguat has been approved for patients with nonsurgical disease or residual pulmonary hypertension despite surgical intervention. This review describes the pathophysiology, risk factors, diagnosis, and management of CTEPH.
- 23 June 2015
- Published by Springer Nature in Current Cardiology Reports
- Vol. 17 (8) , 1-8
Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism
Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when a pulmonary embolism fails to undergo complete thrombolysis leading to vascular occlusion and pulmonary hypertension. Despite the fact that CTEPH is a potential consequence of pulmonary embolism, diagnosis requires a high degree of vigilance as many patients will not have a history of thromboembolic disease. The ventilation perfusion scan is used to evaluate for the possibility of CTEPH although right heart catheterization and pulmonary artery angiogram are needed to confirm the diagnosis. Pulmonary thromboendarterectomy is the first-line treatment for patients who are surgical candidates. Recently, riociguat has been approved for patients with nonsurgical disease or residual pulmonary hypertension despite surgical intervention. This review describes the pathophysiology, risk factors, diagnosis, and management of CTEPH.
- 1 December 2013
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 34 (4) , 811-824
Oral Therapies for Pulmonary Arterial Hypertension
- 1 December 2013
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 34 (4) , 811-824
Oral Therapies for Pulmonary Arterial Hypertension
- Open Access
- 1 April 2013
- Published by Wiley in Pulmonary Circulation
- Vol. 3 (2) , 381-388
A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance, leading to right heart failure and death. Guidelines recommend customization of treatment, necessitating the development of effective strategies for transitioning patients among treatments. In this study, we characterized our experience with patient transitions from parenteral prostacyclin to inhaled iloprost. We retrospectively assessed records from 11 centers of 37 consecutive patients with PAH aged ≥ 18 years who were treated with intravenous (IV) or subcutaneous (SC) prostacyclin analogues and transitioned to inhaled iloprost. The transition period began on the first day of inhaled iloprost with the intent of discontinuing parenteral prostacyclin and ended on the first day on inhaled iloprost free of parenteral prostacyclin. Persistence was defined as the absence of (1) parenteral prostacyclin while remaining on inhaled iloprost during post‐transition Days 1–90 and (2) no reinitiation of parenteral prostacyclin during post‐transition Days 90–365. All patients were clinically stable before transitioning to inhaled iloprost. The mean age was 46.5 years, 70.3% were female, 51.4% had idiopathic PAH, and 43.0% were in New York Heart Association Functional Class III. Among patients with an overlapping transition, the mean transition period was 10.5 days. A transition dosing algorithm was used in 10 patients (27.0%). At one year, 78.4% of the patients remained persistent on inhaled iloprost and 81.1% were free of clinical worsening. In selected patients on background oral PAH therapy, transitioning from parenteral prostacyclin to inhaled iloprost appears safe and feasible and is associated with long‐term success. Further study is needed to define the optimal patient selection criteria and transition algorithm.
- 1 April 2013
- Published by Wiley in Pulmonary Circulation
- Vol. 3 (2) , 381-388
Open AccessA Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance, leading to right heart failure and death. Guidelines recommend customization of treatment, necessitating the development of effective strategies for transitioning patients among treatments. In this study, we characterized our experience with patient transitions from parenteral prostacyclin to inhaled iloprost. We retrospectively assessed records from 11 centers of 37 consecutive patients with PAH aged ≥ 18 years who were treated with intravenous (IV) or subcutaneous (SC) prostacyclin analogues and transitioned to inhaled iloprost. The transition period began on the first day of inhaled iloprost with the intent of discontinuing parenteral prostacyclin and ended on the first day on inhaled iloprost free of parenteral prostacyclin. Persistence was defined as the absence of (1) parenteral prostacyclin while remaining on inhaled iloprost during post‐transition Days 1–90 and (2) no reinitiation of parenteral prostacyclin during post‐transition Days 90–365. All patients were clinically stable before transitioning to inhaled iloprost. The mean age was 46.5 years, 70.3% were female, 51.4% had idiopathic PAH, and 43.0% were in New York Heart Association Functional Class III. Among patients with an overlapping transition, the mean transition period was 10.5 days. A transition dosing algorithm was used in 10 patients (27.0%). At one year, 78.4% of the patients remained persistent on inhaled iloprost and 81.1% were free of clinical worsening. In selected patients on background oral PAH therapy, transitioning from parenteral prostacyclin to inhaled iloprost appears safe and feasible and is associated with long‐term success. Further study is needed to define the optimal patient selection criteria and transition algorithm.
- 1 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111 (8) , 16C-20C
Combination Therapy in Pulmonary Arterial Hypertension
- 1 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111 (8) , 16C-20C
Combination Therapy in Pulmonary Arterial Hypertension
- Open Access
- 1 January 2012
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 6, 19-28
Inhaled treprostinil: a therapeutic review
Peer reviewed article authored by (Channick RN, Voswinckel R, Rubin LJ). Read article or submit your manuscript for publishing.
- 1 January 2012
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 6, 19-28
Open AccessInhaled treprostinil: a therapeutic review
Peer reviewed article authored by (Channick RN, Voswinckel R, Rubin LJ). Read article or submit your manuscript for publishing.
- 31 July 2010
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 26, 5B-11B
Pulmonary hypertension: Classification and treatment
- 31 July 2010
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 26, 5B-11B
Pulmonary hypertension: Classification and treatment
- 1 January 2010
- Published by Elsevier
Contributors